LABETALOL (100 MG TID) AS A BETTER BLOOD PRESSURE MANAGEMENT INTERVENTION FOR THE PREGNANCY INDUCED HYPERTENSION (PIH) CASES THAN THE METHYLDOPA (250 MG TID) MANAGED (PIH) CASES
| Main Author: | Dr. Fareeha Salman, Dr. Ayesha Rauf, Dr. Sohaib Ilyas Cheema |
|---|---|
| Format: | Article Journal |
| Bahasa: | eng |
| Terbitan: |
, 2018
|
| Subjects: | |
| Online Access: |
https://zenodo.org/record/1256357 |
Daftar Isi:
- Background: Hypertension in the course of pregnancy is an important healthcare issue causing maternal mortality in the pregnant women. Our research compares the centrally acting methyldopa and α and β-blocker labetalol efficacy in order to control the incidence of blood pressure which causes hypertension during pregnancy. Material & Methods: We completed this research in the time span of July, 2015 to June, 2017 at Mayo Hospital, Lahore on 120 cases of hypertension during pregnancy. Total sample population was divided in to two groups A & B respectively named as labetalol (100mg tid) and (250 mg tid). In both the groups before and after the treatment diastolic and systolic blood pressure was measured on 1st and 7th day of treatment. During the treatment we observed that BP was reduced, medication was required in order to control the BP and associated side effects of the methyldopa and labetalol. Results: There was a significant observable fall in the measurement of the Labetalol treated group systolic/diastolic BP from first day to the seventh day of the treatment. Every group was observed before and after the management systolic/diastolic BP and it was also compared as on the first day and on the seventh day of the management. Labetalol treated cases were observed with systolic/diastolic BP on 1st day as (150 ± 9 mmHg /100 ± 8 mmHg) respectively and after the intervention when controlled on the seventh day it was measured as (123 ± 9 mmHg / 79 ± 7 mmHg); whereas, systolic/diastolic BP in the group of methyldopa on the first day it was measured as (148 ± 8 mmHg /102 ± 9 mmHg) reduced after seventh day with the help of medical intervention to (125 ± 10 mmHg / 82 ± 6 mmHg). Conclusion: Better hypertensive action was observed in the Labetalol treated group having reduced fetal side effects and maternal mortality in comparison to the group treated with methyldopa; which proves the medication intervention choice in the cases of hypertension during pregnancy. Key Words: Labetalol; Antihypertensive; Pregnancy-induced hypertension and Methyldopa.